N-3 FATTY ACIDS AND RESTENOSIS POST CORONARY ANGIOPLASTY

N-3 脂肪酸与冠状动脉血管成形术后再狭窄

• 批准号: 3353827
• 负责人: ALEXANDER LEAF
• 金额: $ 18.1万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-07-01 至 1989-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3353827
• 关键词: angiography; arachidonate; artery stenosis; aspirin; atherosclerosis; blood chemistry; blood lipid; cardiography; cardiovascular disorder prevention; coronary artery; coronary disorder; diacylglycerols; diet therapy; dietary lipid; dietary supplements; dosage; dosage forms; eicosanoid metabolism; enzyme inhibitors; erythrocyte membrane; fibrinolysis; gas chromatography; gas chromatography mass spectrometry; human subject; inositol phosphates; intraluminal angioplasty; lipid structure; longitudinal human study; marine animal oil; membrane lipids; nutrition related tag; omega 3 fatty acid; phosphatidate; phospholipase A2; phospholipase C; phospholipids; plasminogen activator; platelet activation; prostacyclins; prostaglandin endoperoxide synthase; prostaglandins; radionuclide imaging /scanning; radiotracer; therapy compliance; thromboxanes; vascular resistance

The object of this study is to describe the long term effects of a dietary supplementation of n-3 fatty acids on functional and biochemical parameters in patients with coronary heart disease undergoing elective percutaneous transluminal angioplasty (PTCA). We will use this clinical model to study the effects of n- 3 polyunsaturated fatty acids (PUFAs) on risk indicators of atherosclerosis: serum lipids, platelet activation, thromboxane and prostacyclin formation, and plasma fibrinolytic activity. We will also study the interaction of long chain n-3 PUFAs, precursors of 3-series eicosanoids, with aspirin, an inhibitor of cyclooxygenase, which is used to prevent restenosis after PTCA. We will conduct a detailed analysis of the effects of n-3 PUFAs on initial steps of platelet activation related to the phospholipases C and A2. We will relate the changes observed in myocardial perfusion to effects of n-3 PUFAs on eicosanoid formation, serum lipids, plasma fibrinolytic activity, membrane phospholipid composition, and related enzyme systems. Our findings in this clinical model should be relevant to increasing the understanding of the effects of n-3 PUFAs in preventing atherosclerotic disorders. Though epidemiologic studies indicate an association, this prospective clinical study is designed to demonstrate a causal relationship between n-3 PUFA ingestion and decreased thromboatheromatous vascular disease, if such relationship exists. The biochemical changes thought to be associated with a preventive action of PUFAs will be monitored. Because of a relatively high rate of restenosis (25-35 percent) within one year post PTCA, this study is feasible.

本研究的目的是描述长期影响 膳食补充 n-3 脂肪酸对功能和功能的影响 冠心病患者的生化指标 接受选择性经皮腔内血管成形术 （PTCA）。 我们将使用这个临床模型来研究 n- 3 多不饱和脂肪酸 (PUFA) 的风险指标 动脉粥样硬化：血脂、血小板活化、血栓素 和前列环素的形成以及血浆纤溶活性。 我们 还将研究长链 n-3 PUFA 的相互作用， 3-系列类二十烷酸的前体，与阿司匹林（一种抑制剂） 环氧合酶，用于预防 PTCA 术后再狭窄。 我们将对n-3 PUFA的效果进行详细分析 与磷脂酶相关的血小板活化的初始步骤 C和A2。 我们将观察到的心肌变化联系起来 灌注 n-3 PUFA 对类二十烷酸形成、血清的影响 脂质、血浆纤溶活性、膜磷脂 组成和相关的酶系统。 我们在这个临床模型中的发现应该与增加 了解 n-3 PUFA 在预防中的作用 动脉粥样硬化性疾病。 尽管流行病学研究表明 一个协会，这项前瞻性临床研究旨在 证明 n-3 PUFA 摄入之间的因果关系 并减少血栓粥样硬化性血管疾病（如果有） 关系存在。 生化变化被认为是 与多不饱和脂肪酸预防行动相关的活动将受到监测。 由于再狭窄率相对较高（25-35%） 在PTCA后一年内，这项研究是可行的。